Abstract
Cardiotoxicity (CTX) remains a clinically significant side effect of anti-HER2 therapies. Trastuzumab-related cardiotoxicity is most often manifested by an asymptomatic decrease in left ventricular ejection fraction (LVEF) and less often by clinical heart failure. The aim of this study is to demonstrate the trastuzumab cardiotoxicity with cardiac marker changing and efficacy of steroid and intravenous immunoglobulin (ivig) therapy in the prevention of cardiotoxicity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
